New drug given 1-3months may effectively cut high cholesterol

Credit: Unsplash+

A groundbreaking study has revealed that a new cholesterol-lowering medication, recaticimab, could offer a more flexible and efficient treatment for individuals with high cholesterol.

This medication, injected every one to three months, has shown remarkable results in lowering “bad” cholesterol levels and might revolutionize how we manage heart disease risk.

The research, led by Xin Du, Ph.D., from Beijing Anzhen Hospital, involved 689 participants who were already on statin therapy but still had high cholesterol levels.

The study was conducted over 48 weeks and divided the participants into three groups based on the frequency of recaticimab injections: every 4, 8, or 12 weeks.

Participants experienced a substantial decrease in LDL (“bad”) cholesterol levels compared to placebo groups.

The reduction in cholesterol was observed to be between 51% to 62% across different dosing intervals.

A majority of participants achieved their cholesterol target levels.

  • The medication was well-tolerated with minimal side effects, mainly minor injection site reactions.

Beyond Cholesterol Reduction

Besides lowering LDL cholesterol, recaticimab also positively impacted other lipid parameters associated with heart disease:

  • Lipoprotein(a) levels dropped significantly.
  • Apolipoprotein B levels decreased, suggesting a broader cardiovascular benefit.
  • The total cholesterol content, excluding “good” cholesterol, was also substantially reduced.

Looking Ahead

While recaticimab demonstrated promising results in reducing cholesterol and other heart disease risk factors, further studies are needed to confirm its long-term benefits and potential in reducing heart attack and stroke risks.

The upcoming REMAIN-3 trial will further explore recaticimab’s efficacy in individuals with familial hypercholesterolemia.

Significance for Patients

This study offers a new hope for individuals struggling to manage their cholesterol levels effectively.

Recaticimab’s less frequent dosing schedule could improve adherence to treatment and provide a more convenient option for patients, potentially leading to better overall cardiovascular health.

If you care about heart health, please read studies about the best time to take vitamins to prevent heart disease, and calcium supplements could harm your heart health.

For more information about heart health, please see recent studies about Aspirin linked to higher risk of heart failure, and results showing this drug could reduce heart disease, fatty liver, obesity.

Copyright © 2023 Knowridge Science Report. All rights reserved.